In this study, we found Cystatin SN (CST1), a type 2 cystatin subfamily member, to be highly expressed in nasal polyps from patients with intractable chronic rhinosinusitis (CRS) with nasal polyps, using a whole-transcript analysis with next-generation sequencing. Eosinophilic CRS (ECRS) involves nasal polyps that are refractory and recur immediately after endoscopic sinus surgery. We hypothesized that CST1 may contribute to the pathogenesis of ECRS. We examined the expression of CST1 in nasal polyps from patients with ECRS by assessing mRNA expression levels using real-time PCR and immunohistochemistry. CST1 showed significantly greater expression in the epithelial cells of nasal polyps from patients with ECRS than in those from patients who did not have ECRS (non-ECRS). In particular, CST1 showed very strong expression in patients with severe ECRS. The expression of CST1 may be correlated with the recurrent and refractory nature of ECRS. We examined the function of CST1 using nasal epithelial cells and nasal fibroblasts. Stimulation by a combination of IL-4 plus double-stranded RNA plus CST1 significantly elevated mRNA expression levels and protein levels of TSLP in nasal epithelial cells. Stimulation by TSLP or IL-33 significantly elevated mRNA expression levels of CST1 in nasal epithelial cells. Stimulation of CST1 significantly elevated mRNA expression levels of CCL11 and POSTN in nasal fibroblasts. CST1 could amplify eosinophilic infiltration and T-helper cell type 2 inflammation by interacting with epithelial-derived cytokines and fibroblasts on nasal polyps. CST1 may be involved in the pathogenesis of ECRS, and may contribute to the severity and recurrence of CRS with nasal polyps after endoscopic sinus surgery.
Clinical Relevance
Eosinophilic chronic rhinosinusitis (ECRS) involves nasal polyps that are refractory and recur immediately after endoscopic sinus surgery. CST1 was highly expressed in the nasal polyps from patients with ECRS. CST1 may be involved in the pathogenesis of ECRS, and may contribute to the severity and recurrence of CRS with nasal polyps after endoscopic sinus surgery.
Chronic rhinosinusitis (CRS) is one of the most common chronic diseases and represents a major public health problem all over the world (1) . CRS is defined as the presence of symptoms that include nasal mucus discharge and nasal obstruction lasting longer than 12 weeks.
The pathogenesis of CRS is characterized by prolonged mucosal inflammation of the nose and paranasal sinuses (2, 3) . CRS is typically divided into two subtypes based on the absence or presence of nasal polyps, which are described as CRS without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP), respectively (2, 4, 5) . In Western countries, the nasal mucosa in CRSsNP shows predominant infiltration of neutrophils, whereas nasal polyps in CRSwNP are characterized by eosinophilic infiltration (6) .
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Recently, the number of cases of intractable CRSwNP that recur immediately after endoscopic sinus surgery (ESS) has increased in Japan. The pathology of nasal polyps in patients with refractory CRSwNP shows strong eosinophilic infiltration (7) . Thus, in our study we defined intractable CRSwNP as eosinophilic CRS (ECRS) (8) (9) (10) (11) . Our laboratory reported the precise definition of ECRS as having a refractory and recurrent nature in CRSwNP, consistent with the approach taken by a large-scale epidemiological survey called the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (JESREC). In our study, patients with more than 70 eosinophils/high-power field (HPF) in the nasal polyps were significantly correlated with the recurrence of nasal polyps after ESS, and were classified as having ECRS (11) . We also defined ECRS as CRSwNP with bilateral disease, the presence of nasal polyps, blood eosinophilia, and dominant shadow of ethmoid sinuses in computed tomography (CT) scans, as an algorithm to classify a CRS prognosis before ESS (11) . Concomitantly with blood eosinophilia (.5%), additional exacerbating factors in ECRS include an ethmoid sinus dominant shadow on CT, bronchial asthma, aspirin intolerance, and nonsteroidal antiinflammatory drug intolerance (11) . In CRSwNP, patients without ECRS are also called patients with non-ECRS. This classification, proposed by our laboratory, has been widely used in Japan. Patients with non-ECRS show a good response to ESS even though the ECRS is intractable (8, 12) . It is very hard to treat ECRS, and little is known about its pathogenesis.
Gene profiling technologies, such as RNA sequencing (RNA-seq), can be useful to identify novel disease-related genes for screening to investigate the pathological mechanisms of diseases. We compared the gene expression levels in nasal polyps with those in inferior turbinates of patients with CRSwNP using RNA-seq. We found an increase of Cystatin SN (CST1) expression in the nasal polyps from patients with CRSwNP. CST1 is known to be part of the type 2 cystatin subfamily (13) and is expressed in, e.g., normal salivary glands, the gall bladder, and the ureter (14) . CST1 has a role as a protease inhibitor and inhibits cysteine protease activity by binding tightly with cysteine protease (15) . On the other hand, some studies have shown that CST1 plays an important role in the processes of inflammation and tumorigenesis. In fact, CST1 is highly expressed in various cancer cells, and is elevated in the serum and urine of patients with colorectal cancer (16, 17) . In this study, we investigated the expression of CST1 in nasal polyps from patients with ECRS and analyzed the expression of CST1 according to the disease severity classification in these patients. In addition, we examined the function of CST1 in epithelial cells and fibroblasts of nasal polyps in association with factors induced by T-helper cell type 2 (Th2) inflammation.
Methods
Further details regarding the materials and methods used in this work are provided in the data supplement.
Patients
Nasal polyps were obtained from patients with CRS in the Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medical Science, University of Fukui. All subjects gave informed consent. The subjects' characteristics are presented in Table 1 . Patients with more than 70 eosinophils/ HPF (3400) in their nasal polyp specimens were classified as having ECRS. ECRS cases were classified into four subtypes according to disease severity based on the diagnostic criteria proposed by the JESREC: non-ECRS, mild ECRS, moderate ECRS, and severe ECRS (11) .
RNA-Seq Experiment and Data Analysis
Libraries for sequencing were prepared with total RNA using the TruSeq RNA Sample Prep Kit (Illumina, Inc.) in accordance with the manufacturer's protocol. Paired-end sequencing was performed using the Illumina HiSeq 2000 platform (Illumina). The cutoff value of differential expression was set at an adjusted P value of ,0.05 and logarithm base 2 log fold change . 1 or , 21.
Real-Time PCR
Expression of genes using real-time PCR was quantified with TaqMan Gene Expression Assays and Master Mix (Applied Biosystems). Primer and probe sets were purchased from Applied Biosystems. Quantified aliquots of purified PCR fragments of the target genes were serially diluted and used as standards. mRNA expression levels were normalized to the median expression of the housekeeping gene GAPDH.
Immunohistochemistry
Sections were incubated in rabbit anti-CST1 antibody (aa31-80, LS-B5996; LSBio) overnight at 4 8 C. Sections were incubated in Envision Dual Link System-HRP (Dako) for 1 hour and then incubated in a DAB/Tris solution (Muto Pure Chemicals) for 12 minutes at room temperature. Expression of CST1 in epithelial cells of nasal polyps was analyzed as a semiquantitative score divided into from 0 on 3 (further details regarding semiquantitative score on immunohistochemistry are provided in the data supplement). 
Cell Culture
Nasal epithelial cells and nasal fibroblasts were obtained from the nasal polyps of patients with ECRS as previously described (18) . rhIL-4, rhCST1, rhTSLP, and rhIL-33 were purchased from R&D Systems, and double-stranded RNA (dsRNA) was purchased from Tocris Bioscience. siRNAs against CRLF2, IL1RL1, and a negative control were purchased from Applied Biosystems.
ELISA TSLP concentrations were measured using a specific ELISA kit (R&D Systems). Periostin concentrations were measured using a specific ELISA kit (Shino-Test).
Statistical Analysis
All data are reported as means 6 SEM unless otherwise noted. Differences between groups were analyzed by one-way ANOVA with Dunnett's post hoc test or t test. Correlations were assessed by the Pearson correlation. A P value of ,0.05 was considered statistically significant.
Results

Expression of CST1 in Nasal Polyps was Positively Correlated with the Severity of ECRS
To identify genes differentially expressed in nasal polyps from patients with CRSwNP, we performed RNA-seq using a nextgeneration sequencer. When we compared the expression levels in the inferior turbinates and nasal polyps from patients with CRSwNP, we found that 3,574 transcripts were statistically significantly different (P , 0.05). A total of 1,264 transcripts were upregulated in the nasal polyps (log fold change . 1), and 899 transcripts were downregulated (log fold change , 21). The 10 most highly expressed genes in the nasal polyps were POSTN, CST1, SERPINB3, CCL18, IGFBP3, TUBB4B, ALOX15, CSTB, SERPINF1, and TPPP3. Among these 10 genes, we focused on CST1. CST1 showed a 27.2-fold-change higher expression in the nasal polyps from patients with CRSwNP (FPKM = 629) compared with the inferior turbinates (FPKM = 8.53) (log fold change 4.77, adjusted P value , 0.05; Table E1 in the data supplement).
To examine which types of nasal polyps express high levels of CST1, we analyzed the ORIGINAL RESEARCH mRNA expression levels of CST1 in the nasal polyps of patients with CRSwNP, obtained by ESS. Patients with more than 70 eosinophils/HPF in their nasal polyps were classified as having ECRS according to the diagnostic criteria proposed by the JESREC (11) . The mRNA expression levels of CST1 were significantly higher in nasal polyps from patients with ECRS (19.5 3 10 5 6 6.33 3 10 5 copies/ng) compared with patients with non-ECRS (1.80 3 10 5 6 1.51 3 10 5 copies/ng; P , 0.01; Figure 1A ). We then investigated the expression of CST1 protein in the nasal polyps from patients with and without ECRS using immunohistochemistry. Consistent with the results of the analysis of mRNA expression levels using real-time PCR, CST1 was more strongly expressed in the nasal polyps from patients with ECRS compared with those from the patients with non-ECRS ( Figures 1B and 1C) . CST1 was expressed in the epithelial cells of the nasal polyps, but not in the stromal cells. The semiquantitative score classified in 3 from 0 according to the frequency of CST1 expression in the epithelial cells was also significantly higher in the epithelial cells of the nasal polyps from patients with ECRS (1.55 6 0.12) than those from the patients with non-ECRS (0.80 6 0.10, P , 0.001; Figures 1D and E1) . Thus, these findings suggest that the epithelial cells of the nasal polyps from patients with ECRS showed higher expression of CST1 than those from patients with non-ECRS.
Previously, our laboratory had proposed using the disease severity classification of ECRS used by the JESREC (11) . According to this algorithm using blood eosinophilia, ethmoid sinus dominant shadow in CT scans, comorbidity of bronchial asthma, aspirin intolerance, and nonsteroidal antiinflammatory drug intolerance, CRSwNP was classified in patients with non-ECRS or mild, moderate, or severe ECRS (11) . The four groups were significantly correlated with recurrence and refractory rates. We analyzed the semiquantitative score of CST1 protein expression using immunohistochemistry according to this disease severity classification. Severe ECRS showed the highest expression of CST1 in patients with CRSwNP (non-ECRS: 0.57 6 0.09; mild ECRS: 1.32 6 0.19; moderate ECRS: 1.22 6 0.15; severe ECRS: 1.80 6 0.18) ( Figure  1E ). As severe ECRS showed the strong eosinophilic infiltration in the nasal polyps, we examined the correlation between CST1 and eosinophils in nasal polyps. In CST1 mRNA expression (real-time PCR, r = 0.565, P , 0.001) and semiquantitative score of CST1 protein expression (immunohistochemistry, r = 0.323, P , 0.001), CST1 were positively correlated with the eosinophil number in nasal polyps (Figures 2A and 2B) .
These results demonstrated that CST1 was expressed more strongly in the epithelial cells of the nasal polyps from patients with ECRS than in those from patients with non-ECRS. CST1 showed particularly strong expression in epithelial cells from patients with severe ECRS.
CST1 Contributes to the Progression of Th2/Eosinophilic Inflammation via TSLP and Fibroblasts
We examined the correlation between CST1 and TSLP, IL-33, CCL11, and POSTN in nasal polyps from patients with CRSwNP, and found that CST1 mRNA expression in nasal polyps from patients with CRSwNP was positively correlated with mRNA expression of TSLP (r = 0.623, P , 0.001), IL-33 (r = 0.350, P , 0.05), CCL11 (r = 0.413, P , 0.05), and POSTN (r = 0.834, P , 0.001) in the nasal polyps (Figures 3A-D) . We Nasal epithelial cells were stimulated with TSLP (1-100 ng/ml) (C) or IL-33 (1-100 ng/ml) (D) for 6 hours. Total RNA was harvested and mRNA levels of CST1 were analyzed using real-time PCR. The results are presented as means 6 SEM of six independent experiments; these experiments were examined as technical duplicates. *P , 0.05, **P , 0.01.
hypothesized that the association of CST1 with these factors is indicative of Th2/eosinophilic inflammation, and therefore examined the function of CST1 in epithelial cells and fibroblasts isolated from nasal polyps. TSLP and IL-33 have been associated with eosinophilia and the pathogenesis of ECRS (19, 20) . To examine the correlation between CST1 and TSLP, we used nasal epithelial cells isolated from nasal polyps of patients with ECRS. Nasal epithelial cells were stimulated for 6 hours by IL-4 (100 ng/ml) and/or dsRNA (50 mg/ml) and/or CST1 (100 ng/ml), and then total RNA was harvested. We analyzed the mRNA expression levels of TSLP using real-time PCR. The mRNA expression levels of TSLP were significantly elevated in IL-4 plus dsRNA ( copies/ng; P , 0.01; Figure 4A ). In addition, we measured the production of TSLP in cell-free supernatants stimulated for 24 hours using ELISA to analyze this reaction in protein levels. As with the mRNA expression levels in the epithelial cells, the protein levels of TSLP in the supernatants were also significantly elevated in IL-4 plus dsRNA plus CST1 (40.0 6 2.46 pg/ml) compared with the stimulation by IL-4 plus dsRNA (4.00 6 2.15 pg/ml; P , 0.01; Figure 4B ). IL-33 mRNA was not significantly elevated by IL-4 plus dsRNA plus CST1 (data not shown).
To investigate the effects of TSLP and IL-33 on CST1 expression, we stimulated nasal epithelial cells for 6 hours by TSLP (1-100 ng/ml) or IL-33 (1-100 ng/ml), and then harvested the total RNA. We analyzed the mRNA expression levels of CST1. The mRNA expression levels of CST1 were significantly elevated by TSLP stimulation at a concentration of 100 ng/ml (1.36 3 10 2 6 0.16 3 10 2 copies/ng vs. control: 0.37 3 10 2 6 0.17 3 10 2 copies/ng; P , 0.01; Figure 4C ). The stimulation of IL-33 also elevated the expression of CST1 (100 ng/ml: 1.27 3 10 2 6 0.20 3 10 2 copies/ng vs. control: 0.20 3 10 2 6 0.07 3 10 2 copies/ng; P , 0.05; Figure 4D ). As previous studies found that epithelial cells in nasal polyps and normal human bronchial epithelial cells expressed TSLP and IL-33 receptors (20) (21) (22) , it was assumed that TSLP or IL-33 directly led to increased CST1 expression. To elucidate the relationship between TSLP or IL-33 signaling and CST1 expression in nasal epithelial cells, we knocked down the receptor for TSLP or IL-33 by siRNA. Nasal epithelial cells were transfected with siRNA against CRLF2 (the receptor for TSLP), IL1RL1 (the receptor for IL-33), or negative control siRNA. Epithelial cells were then stimulated with TSLP (100 ng/ml) or IL-33 (100 ng/ml). The mRNA expression levels of CRLF2 in nasal epithelial cells were significantly suppressed by transfection with specific siRNAs compared with cells transfected with the negative control siRNA (negative control siRNA: 20.2 6 5.19 vs. CRLF2 siRNA: 4.27 6 1.66; P , 0.05; Figure 5A ). Induction of CST1 by TSLP was significantly inhibited by transfection with siRNA against CRLF2 compared with the Transfected cells were further stimulated with TSLP (100 ng/ml) (C) or IL-33 (100 ng/ml) (D) for 6 hours. Total RNA was harvested and the mRNA levels of CST1 were analyzed using real-time PCR. The results are presented as means 6 SEM of six independent experiments; these experiments were examined as technical duplicates. *P , 0.05, **P , 0.01.
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negative control siRNA (negative control siRNA: 2.63 3 10 2 6 0.37 3 10 2 vs. CRLF2 siRNA: 0.67 3 10 2 6 0.40 3 10 2 ; P , 0.05; Figure 5C ). The mRNA expression levels of IL1RL1 in nasal epithelial cells were also suppressed by transfection with specific siRNAs compared with cells transfected with the negative control siRNA (negative control siRNA: 13.6 3 10 3 6 1.23 3 10 3 vs. IL1RL1 siRNA: 3.01 3 10 3 6 0.30 3 10 3 ; P , 0.01; Figure 5B ). Induction of CST1 by IL-33 was significantly inhibited by transfection with siRNA against IL1RL1 compared with the negative control siRNA (negative control siRNA: 2.82 3 10 2 6 0.57 3 10 2 vs. IL1RL1 siRNA: 1.19 3 10 2 6 0.62 3 10 2 ; P , 0.01; Figure 5D ). These results suggested that these responses were mediated via TSLP and IL-33 signaling pathways in nasal epithelial cells.
CCL11 is the representative factor that recruits eosinophils. In the RNA-seq analysis of nasal polyps and inferior turbinates from patients with CRSwNP, CCL11 tended to be highly expressed in nasal polyps, albeit without a statistically significant difference (log fold change . 1; Table E1 ). To examine the effect of CST1 on CCL11 in nasal polyps, we stimulated nasal epithelial cells or nasal fibroblasts for 6 hours with CST1 (1-100 ng/ml) and analyzed the mRNA expression levels of CCL11. CST1 did not upregulate CCL11 mRNA expression levels in nasal epithelial cells (100 ng/ml: 3.72 6 1.11 copies/ng vs. control: 4.11 6 0.62 copies/ng; not significant; Figure 6A ), whereas there were significantly elevated mRNA expression levels of CCL11 in nasal fibroblasts (100 ng/ml: 10.0 3 10 2 6 2.70 3 10 2 copies/ng vs. control: 0.17 3 10 2 6 0.04 3 10 2 copies/ng; P , 0.05; Figure 6B ). POSTN (periostin) showed very high expression levels in the nasal polyps using a nextgeneration sequencer (log fold change . 1, adjusted P value , 0.01; Table E1 ).
Fibroblasts isolated from nasal polyps were stimulated with CST1 (1-100 ng/ml), and the mRNA expression levels of POSTN were analyzed. The stimulation by CST1 significantly elevated the mRNA expression of POSTN in nasal fibroblasts (100 ng/ml: 4.50 3 10 5 6 0.64 3 10 5 copies/ng vs. control: 1.94 3 10 5 6 0.12 3 10 5 copies/ng; P , 0.05; Figure 6C ). Nasal fibroblasts were stimulated with CST1 (100 ng/ml) for 24 hours, and cell-free supernatants were used to measure periostin levels by ELISA, which revealed that the protein levels of periostin in these supernatants were also significantly elevated with CST1 stimulation (100 ng/ml: 3.78 3 10 3 6 0.21 3 10 3 pg/ml vs. control: 3.17 3 10 3 6 0.11 3 10 3 pg/ml; P , 0.05; Figure 6D ). These results suggest that CST1 from epithelial cells may contribute to amplification of eosinophilic infiltration and Th2 inflammation via interaction with TSLP and IL-33 in epithelial cells, and CCL11 and periostin in fibroblasts.
Discussion
Next-generation sequencing can often provide enormous amounts of sequencing data for a small RNA fraction, and can detect many types of genomic variations (23) . Using next-generation sequencing, we identified diversity genes associated with CRSwNP. In particular, CST1 showed a 27.2-fold-change higher expression in the nasal polyps compared with inferior turbinate mucosa. In our previous study of RNA-seq analysis, CST1 expression was higher in nasal polyps from patients with Figure 6 . Effect of CST1 on CCL11 and POSTN released by nasal fibroblasts. (A) Nasal epithelial cells were stimulated with CST1 (100 ng/ml) for 6 hours. Total RNA was harvested and the mRNA levels of CCL11 were analyzed by real-time PCR. (B and C) Nasal fibroblasts were stimulated with CST1 (1-100 ng/ml) for 6 hours. Total RNA was harvested and the mRNA levels of CCL11 (B) and POSTN (C) were analyzed by real-time PCR. (D) Nasal fibroblasts were stimulated with CST1 (100 ng/ml) for 24 hours. The concentrations of periostin protein in culture supernatants were measured by ELISA. The results are presented as means 6 SEM of six independent experiments; these experiments were examined as technical duplicates. *P , 0.05.
ECRS than in those from patients with non-ECRS (24) . Expression of CST1 using real-time PCR and immunohistochemistry was significantly higher in nasal polyps from patients with ECRS than in those from patients with non-ECRS. In addition, among the patients with ECRS, those with severe ECRS expressed the highest levels of CST1. These findings suggest that the expression of CST1 may be correlated with the recurrent and refractory nature of ECRS. Kouzaki and colleagues reported that patients with ECRS showed significantly lower expression of a protease inhibitor, cystatin A, in the nasal epithelium compared with patients with non-ECRS, and that cystatin A played a protective role in the airway epithelium (25) . This result is in contrast to the high expression of CST1 in nasal polyps. Cystatin A is part of the type 1 cystatin subfamily, whereas CST1 belongs to the type 2 cystatin subfamily and has other roles that differ from those of the protease inhibitor, such as involvement in inflammation and interaction with the other cystatin family (17, 26, 27) . CST1 is likely to be upregulated in the Th2 environment in the nasal mucosa (28) . We also previously reported that the expression of CST1 was specifically upregulated in patients with allergic rhinitis during natural allergen exposure, and CST1 was involved in the change of barrier function (29) . The high expression of CST1 may act as a pathology exacerbation factor in ECRS. TSLP and IL-33 have key roles in Th2-type inflammation (30) (31) (32) . These cytokines act on various cells, such as Th2 cells, mast cells, basophils, eosinophils, macrophages, and type 2 innate lymphoid cells, and activate type 2 inflammation in allergic diseases such as bronchial asthma, allergic rhinitis, and allergic dermatitis (33) (34) (35) . In the RNA-seq analysis of nasal polyps and inferior turbinates from patients with CRSwNP, IL-33 expression levels were significantly higher in the nasal polyps than in the inferior turbinates of patients with CRSwNP (log fold change . 1, adjusted P value , 0.01; Table E1 ). TSLP expression in the nasal polyps was comparable to that in the inferior turbinates of patients with CRSwNP (Table E1 ). The mRNA expression of CST1 in the nasal polyps was positively correlated with mRNA expression of TSLP and IL-33 in the nasal polyps. Recently, several studies have shown that epithelial-derived cytokines may contribute to inflammation in eosinophilic CRSwNP (5, 36, 37) . TSLP mRNA was significantly elevated in nasal polyps with eosinophilic infiltration, and TSLP may have a key role in type 2 inflammation in ECRS (19, 20) . As for IL-33, the epithelial cells of recalcitrant CRSwNP have shown high expression of IL-33 compared with therapy-responsive CRSwNP (38, 39) . There is no doubt that epithelial-derived factors are involved in the pathogenesis and severity of ECRS. However, it remains unclear how these mechanisms increase epithelial-derived cytokines in ECRS. In our study, CST1 was particularly expressed in the epithelial cells of the nasal polyps from patients with ECRS, rather than in the stroma cells. The stimulation of IL-4 plus dsRNA elevated TSLP mRNA in both normal human bronchial epithelial cells (40) and nasal epithelial cells. Furthermore, compared with the stimulation by IL-4 plus dsRNA, the combination of IL-4 plus dsRNA plus CST1 significantly elevated both the mRNA expression levels and protein levels of TSLP in nasal epithelial cells. Thus, CST1 may show a synergistic effect with IL-4 and dsRNA. Th2 cytokines and infection are important exacerbation factors in the pathogenesis of ECRS. ECRS is characterized by Th2-dominant eosinophil inflammation, and infection can enhance the inflammation of the Th2 response by releasing epithelial-derived cytokines in the Th2 environment (2, 8) . In our previous study, to examine the direct effect of eosinophils on CST1, we stimulated a human eosinophilic cell line (Eol-1) by CST1 and extracted the total RNA. We analyzed the mRNA expression levels of ECP and MBP, which are granule proteins secreted by eosinophils. CST1 did not upregulate the ECP and MBP mRNA expression levels (data not shown). We believe that TSLP is increased by CST1, IL-4, and dsRNA, and then amplifies eosinophilic infiltration and Th2 inflammation via Th2 cytokines released by Th2 cells and type 2 innate lymphoid cells in the nasal polyps of patients with ECRS ( Figure 7 ). In addition, stimulation by TSLP or IL-33 increased the mRNA expression levels of CST1 via TSLP and IL-33 signaling pathways in nasal epithelial cells. These results suggest that CST1 is involved in the formation and refractory nature of nasal polyps from patients with ECRS through the positive-feedback loop between TSLP and IL-33 and CST1 (Figure 7 ). The amplification of type 2 inflammation in ECRS is caused by various cells, including eosinophils, mast cells, basophils, dendritic cells, macrophages, Th2 cells, B cells, and fibroblasts. Fibroblasts are increased in nasal polyps and are associated with the disease severity of CRSwNP (41, 42) . Fibroblasts induce the recruitment of inflammatory cells and are an important source of extracellular matrix proteins involved in inflammatory reactions. These major components of nasal polyps are strongly involved with the formation of intractable nasal polyps. The stimulation of CST1 in fibroblasts isolated from nasal polyps elevated CCL11 mRNA. The release of chemokines such as CCL11 and RANTES can recruit eosinophils through CCR3, which is expressed on eosinophils. CCL11 expression, which was previously reported to be increased in nasal polyps, is closely involved in eosinophil recruitment in CRSwNP (43) . In the epithelial cells of nasal polyps, CST1 may induce the migration of eosinophils by amplifying the release of CCL11 derived from fibroblasts, in addition to the effect of TSLP ( Figure  7 ). In our whole-transcript analysis, periostin (POSTN) showed the strongest expression in the nasal polyps. Periostin is an extracellular matrix protein that is produced in fibroblasts and is associated with Th2/eosinophilic inflammation (44, 45) . Periostin upregulates the effector functions of eosinophils (46) . The stimulation of CST1 in nasal fibroblasts elevated periostin mRNA and protein levels. CST1 may play a role in the pathogenesis of ECRS via periostin in fibroblasts ( Figure 7 ). Further studies of the relationship between CST1 and various factors associated with ECRS could be useful to clarify the pathogenesis of ECRS.
In summary, we investigated the expression of CST1 in ECRS. CST1 showed strong expression in the epithelial cells of nasal polyps from patients with severe ECRS. CST1 may contribute to the severity and recurrence of ECRS by interacting with various factors that exacerbate the pathogenesis of ECRS, such as Th2 cytokines, infection, TSLP, and fibroblasts. n Author disclosures are available with the text of this article at www.atsjournals.org.
